A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

This study tests a new oral drug called XZP-5955 in patients with advanced or metastatic solid tumors that have a specific genetic change called an NTRK or ROS1 gene fusion — a type of mutation that drives cancer growth and can be targeted by this drug. **You may be eligible if...** - You are 18 or older with confirmed locally advanced or metastatic solid tumor - Your cancer is NTRK or ROS1 fusion positive (confirmed by an approved laboratory) - Your cancer has progressed or stopped responding to available treatments - You are in good health (ECOG 0–1) with at least 3 months life expectancy - You have adequate blood, liver, and kidney function - You are willing to use contraception if of childbearing potential **You may NOT be eligible if...** - You received anti-tumor therapy within 4 weeks before starting the study drug - You have symptomatic brain or spinal cord metastases requiring steroids - You have a known history of immune deficiency or HIV - You have active hepatitis B or C - You have a serious cardiovascular condition - You are pregnant or breastfeeding - You have significant difficulty swallowing or absorbing oral medications Talk to your doctor to see if this trial is right for you.